Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside

• Main Authors: Sijia Tao (Author), Keivan Zandi (Author), Leda Bassit (Author), Yee Tsuey Ong (Author), Kiran Verma (Author), Peng Liu (Author), Jessica A. Downs-Bowen (Author), Tamara McBrayer (Author), Julia C. LeCher (Author), James J. Kohler (Author), Philip R. Tedbury (Author), Baek Kim (Author), Franck Amblard (Author), Stefan G. Sarafianos (Author), Raymond F. Schinazi (Author)
• Format: Book
• Published: Elsevier, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Remdesivir, a monophosphate prodrug of nucleoside analog GS-441524, is widely used for the treatment of moderate to severe COVID-19. It has been suggested to use GS-441524 instead of remdesivir in the clinic and in new inhalation formulations. Thus, we compared the anti-SARS-CoV-2 activity of remdes...